CDX Holdings (Irving, Texas) said that George Poste, DVM, PhD, was named non-executive vice chairman and chief scientific advisor of CDX Holdings and non-executive chairman of CMDx. Poste has been a director of Caris Dx, and now CDX Holdings, since November of 2006. He also acts as senior technical advisor to Caris, Ltd., which owns a controlling stake in CDX Holdings. CDX Holdings is a newly-formed holding company that is the parent company of Caris Diagnostics (Caris Dx) and Caris Molecular Diagnostics (CMDx).
DiagnoCure (Quebec) said that four colorectal cancer opinion leaders have agreed to serve on the advisory board of its subsidiary DiagnoCure Oncology Laboratories. The new advisory board members are Edith Mitchell, MD, clinical professor of medicine & medical oncology at Jefferson Kimmel Cancer Center; Stanley Hamilton, MD, professor and head, Division of Pathology & Laboratory Medicine, at M.D. Anderson Cancer Center; Daniel Sargent, PhD, professor of statistics and oncology and director of cancer statistics at Mayo Clinic; and Martin Weiser, MD, surgical oncologist at Memorial Sloan-Kettering Cancer Center. DiagnoCure is a developer of cancer diagnostic tests and a provider of laboratory services.
DxS (Manchester, UK) reported the appointment of Ron Long as non-executive director. Long holds board positions including Medivir AB, and Procognia Israel Ltd. DxS is a molecular diagnostics company specializing in cancer treatment.
IRIS International (Chatsworth, California) said that Edward Voboril has been elected to the company's board, expanding the board to eight members. Voboril is currently chairman of the board of Analogic. Voboril retired this year as chairman of Greatbatch. IRIS makes automated in vitro diagnostics.